NAGE Q1 2024 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M-1.8% YoY

Gross Profit

$13M60.7% margin

Operating Income

-$731,000-3.3% margin

Net Income

-$492,000-2.2% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+4.5%

Cash Flow

Operating Cash Flow

$295,000

Free Cash Flow

$254,000

Stock-Based Comp.

$984,000

Balance Sheet

Total Assets

$54M

Total Liabilities

$25M

Stockholders' Equity

$29M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$23M	-1.8%
Gross Profit	$13M	$14M	-0.5%
Operating Income	-$731,000	-$2M	+62.9%
Net Income	-$492,000	-$2M	+74.1%